Literature DB >> 22943045

Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer.

Charles A Kunos1.   

Abstract

Cervical and vaginal cancers remain serious health problems. Worldwide, more than 530,000 women annually are diagnosed with these diseases, with most new incident cases occurring in nations with limited health resources and underdeveloped screening programs. For women whose disease is too bulky or widespread for surgery, radiochemotherapy should be looked upon as the standard of care. Randomized clinical trials have indicated that radiochemotherapy strategies that disrupt the repair of damaged DNA are key to the management of advanced stage cervical and vaginal cancers. Here, from a viewpoint of cancer cell molecular biology, treatments for advanced stage cervical and vaginal cancers are discussed.

Entities:  

Year:  2012        PMID: 22943045      PMCID: PMC3429879     

Source DB:  PubMed          Journal:  Oncol Hematol Rev        ISSN: 2052-3815


  50 in total

1.  Are we making progress in curing advanced cervical cancer?

Authors:  Gillian Thomas
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

2.  Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks.

Authors:  A Chabes; L Thelander
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

3.  Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; John Pink; Song-Mao Chiu; Tammy Stefan; James Jacobberger; Timothy J Kinsella
Journal:  Radiat Res       Date:  2010-09-10       Impact factor: 2.841

4.  Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study.

Authors:  Rachelle Lanciano; Alison Calkins; Brian N Bundy; Groesbeck Parham; Joseph A Lucci; David H Moore; Bradley J Monk; Dennis M O'Connor
Journal:  J Clin Oncol       Date:  2005-10-17       Impact factor: 44.544

5.  Efficacy of screening for cervical cancer: a review.

Authors:  D S Guzick
Journal:  Am J Public Health       Date:  1978-02       Impact factor: 9.308

6.  Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein.

Authors:  Charles A Kunos; Song-mao Chiu; John Pink; Timothy J Kinsella
Journal:  Radiat Res       Date:  2009-12       Impact factor: 2.841

7.  Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis.

Authors:  S Eriksson; A Gräslund; S Skog; L Thelander; B Tribukait
Journal:  J Biol Chem       Date:  1984-10-10       Impact factor: 5.157

8.  Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.

Authors:  Patricia J Eifel; Kathryn Winter; Mitchell Morris; Charles Levenback; Perry W Grigsby; Jay Cooper; Marvin Rotman; David Gershenson; David G Mutch
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

9.  A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.

Authors:  Peter G Rose; Koen Degeest; Scott McMeekin; Nancy Fusco
Journal:  Gynecol Oncol       Date:  2007-08-03       Impact factor: 5.482

10.  Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 protein.

Authors:  P S Huang; D R Patrick; G Edwards; P J Goodhart; H E Huber; L Miles; V M Garsky; A Oliff; D C Heimbrook
Journal:  Mol Cell Biol       Date:  1993-02       Impact factor: 4.272

View more
  4 in total

1.  Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Adam Kresak; Dawn Dawson; James Jacobberger; Bin Yang; Fadi W Abdul-Karim
Journal:  Int J Gynecol Cancer       Date:  2012-11       Impact factor: 3.437

2.  Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers.

Authors:  Charles A Kunos; Tomas Radivoyevitch; Steven Waggoner; Robert Debernardo; Kristine Zanotti; Kimberly Resnick; Nancy Fusco; Ramon Adams; Raymond Redline; Peter Faulhaber; Afshin Dowlati
Journal:  Gynecol Oncol       Date:  2013-04-18       Impact factor: 5.482

3.  Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis.

Authors:  Charles A Kunos; Kathryn Winter; Adam P Dicker; William Small; Fadi W Abdul-Karim; Dawn Dawson; Anuja Jhingran; Richard Valicenti; Joanne B Weidhaas; David K Gaffney
Journal:  Int J Gynecol Cancer       Date:  2013-05       Impact factor: 3.437

4.  Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for Locally Advanced Stage Uterine Cervix or Vaginal Cancers.

Authors:  Charles A Kunos; Stephen J Andrews; Kathleen N Moore; Hye Sook Chon; S Percy Ivy
Journal:  Front Oncol       Date:  2019-10-15       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.